XBI vs. SMMT
Compare and contrast key facts about SPDR S&P Biotech ETF (XBI) and Summit Therapeutics Inc. (SMMT).
XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: XBI or SMMT.
Key characteristics
| XBI | SMMT | |
|---|---|---|
| YTD Return | 13.49% | 1,123.37% |
| 1Y Return | 29.59% | 1,571.73% |
| 3Y Return (Ann) | -7.74% | 71.12% |
| 5Y Return (Ann) | 4.28% | 86.95% |
| Sharpe Ratio | 1.03 | 5.37 |
| Daily Std Dev | 28.50% | 297.58% |
| Max Drawdown | -63.89% | -95.75% |
| Current Drawdown | -41.73% | 0.00% |
Correlation
The correlation between XBI and SMMT is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
XBI vs. SMMT - Performance Comparison
In the year-to-date period, XBI achieves a 13.49% return, which is significantly lower than SMMT's 1,123.37% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
XBI vs. SMMT - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and Summit Therapeutics Inc. (SMMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
XBI vs. SMMT - Dividend Comparison
XBI's dividend yield for the trailing twelve months is around 0.13%, while SMMT has not paid dividends to shareholders.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
XBI SPDR S&P Biotech ETF | 0.13% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% | 1.07% | 0.17% |
SMMT Summit Therapeutics Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
XBI vs. SMMT - Drawdown Comparison
The maximum XBI drawdown since its inception was -63.89%, smaller than the maximum SMMT drawdown of -95.75%. Use the drawdown chart below to compare losses from any high point for XBI and SMMT. For additional features, visit the drawdowns tool.
Volatility
XBI vs. SMMT - Volatility Comparison
The current volatility for SPDR S&P Biotech ETF (XBI) is 6.02%, while Summit Therapeutics Inc. (SMMT) has a volatility of 52.19%. This indicates that XBI experiences smaller price fluctuations and is considered to be less risky than SMMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.